Yixintang Pharmaceutical Group Second Quarter 2024 Earnings: Misses Expectations

Simply Wall St · 6d ago

Yixintang Pharmaceutical Group (SZSE:002727) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥4.21b (flat on 2Q 2023).
  • Net income: CN¥40.0m (down 85% from 2Q 2023).
  • Profit margin: 1.0% (down from 6.3% in 2Q 2023).
  • EPS: CN¥0.067 (down from CN¥0.45 in 2Q 2023).
earnings-and-revenue-history
SZSE:002727 Earnings and Revenue History September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Yixintang Pharmaceutical Group Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 8.6%. Earnings per share (EPS) also missed analyst estimates by 66%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Consumer Retailing industry in China.

Performance of the Chinese Consumer Retailing industry.

The company's shares are up 4.7% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Yixintang Pharmaceutical Group.